Dan Williams

PhD, CEO of SynaptixBio

Press citations per month · linked articles

Aug 2026Sept 2026Oct 2026Nov 2026to date

press citation on 1 topic since 10 Aug 2026 · last quoted 10 Aug 2026

02 Quoted on · 1 of 29 topics

Rare diseases1

Open the topic

Dan Williams: key facts

Kind of voice: Academic
Role: PhD, CEO of SynaptixBio
Quoted on: Rare diseases
Tracked press citations: 1
Most recently quoted: 10 Aug 2026

03 Profile

04 On the record · press

What Dan Williams has said

By outlet · linked articles

scientistlive.com1

Where Dan Williams has been quoted

01UK investment in rare disease biotechs is lagging other regions, says SynaptixBio - Scientist Livescientistlive.com · 10 Aug 2026

Verbatim

“The US dominates because the PRV program creates a highly valuable and, more importantly, tradable asset. VCs and private equity firms are far more willing to invest in rare disease biotechs simply because they provide a financial return on investment.”

PhD, CEO of SynaptixBio · Rare diseases · scientistlive.com · 10 Aug 2026 · Read the article

Related media coverage

Recent UK press coverage of their topics, not necessarily citing them directly.

Coventry tot's heartbreaking health battle after 'extremely rare' diagnosiscoventrytelegraph.net
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdlereuters.com
'Immoral lottery' - Mum's plea after losing daughter to rare diseasethewestmorlandgazette.co.uk

Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 12 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.